Influence of Exceptional Patient Characteristics on Everolimus Exposure
Phase of Trial: Phase IV
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics
- Acronyms INPRES
- 19 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
- 19 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 01 Nov 2016 Results assessing the impact of hematocrit on pharmacokinetics and pharmacodynamics of everolimus in cancer patients (n=73) from THYRRAD and INPRES trials using semi-physiological pharmacokinetic model, published in the Clinical Pharmacokinetics Journal.